Bridging Nonclinical Data to Starting Dose Selection in Phase 1 Trials Bridging Nonclinical Data to Starting Dose Selection in Phase 1 Trials The selection of the starting dose in Phase 1 clinical trials is a critical decision-making process that integrates nonclinical data. This paper aims to elucidate the nonclinical requirements necessary for Investigational New Drug (IND) submissions, particularly focusing on the first-in-human IND package, GLP toxicology studies, and safety pharmacology requirements. The framework discussed herein aligns with regulatory expectations set forth by the US FDA, EMA, and MHRA, ensuring that pharmaceutical professionals are equipped with the relevant knowledge to navigate…

Designing Nonclinical Programs to Support Oncology First in Human INDs Designing Nonclinical Programs to Support Oncology First in Human INDs Oncology drug development presents unique challenges, especially when preparing for the first in human (FIH) trials. The regulatory framework set by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the UK Medicine and Healthcare products Regulatory Agency (MHRA) imposes specific nonclinical requirements to ensure the safety and efficacy of new treatments. This article will provide a comprehensive overview of the essential nonclinical programs necessary for supporting oncology FIH Investigational New Drug (IND) submissions….

GLP vs Non-GLP Data: What is Acceptable in Early IND Submissions Understanding Acceptable GLP and Non-GLP Data in Early IND Submissions The regulatory landscape surrounding initial IND (Investigational New Drug) submissions is complex and requires a thorough understanding of the nonclinical requirements, particularly regarding Good Laboratory Practice (GLP) and non-GLP data. This article will delve into the differences between GLP and non-GLP data, their implications for the first in human IND package, and what regulatory agencies such as the FDA, EMA, and MHRA expect from pharmaceutical companies during early development phases. 1. Introduction to IND Nonclinical Requirements The IND application…

Toxicology, Safety Pharmacology and DMPK Studies Required Before IND Filing Toxicology, Safety Pharmacology and DMPK Studies Required Before IND Filing In the pharmaceutical development landscape, the transition from preclinical research to clinical trials is a pivotal moment. Before submitting an Investigational New Drug (IND) application to the US FDA or corresponding regulatory authorities in the EU and the UK, stakeholders must thoroughly understand essential nonclinical requirements. This article seeks to elucidate the critical toxicology studies, safety pharmacology assessments, and drug metabolism and pharmacokinetics (DMPK) requirements necessary for a successful first in human IND submission. Introduction to IND Nonclinical Requirements The…

How to build a nonclinical package for first in human IND applications How to Build a Nonclinical Package for First in Human IND Applications Introduction Submitting an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) marks a critical milestone in the drug development process, particularly for therapies intended for first-in-human (FIH) studies. The preparation of a nonclinical package is an essential component of the IND application, as it provides the necessary safety data to support human trials. This article delves into the essential elements required to construct a comprehensive nonclinical package for FIH IND applications,…

Nonclinical Requirements for IND Submissions: A Practical FDA Readiness Checklist Nonclinical Requirements for IND Submissions: A Practical FDA Readiness Checklist The submission of an Investigational New Drug (IND) application is a critical milestone in drug development, particularly for applicants seeking to advance their therapeutic candidates to clinical trials. This article serves as a comprehensive guide to the nonclinical requirements mandated by the U.S. Food and Drug Administration (FDA) and offers insights into the essential documentation and data that must be compiled in order to ensure FDA readiness. The considerations outlined are pertinent not only for the U.S. regulatory landscape but…

Use of Literature, Workshare, and Prior Findings to Streamline Nonclinical IND Work Use of Literature, Workshare, and Prior Findings to Streamline Nonclinical IND Work The process of preparing for an Investigational New Drug (IND) application is critical in the pharmaceutical development cycle. It necessitates extensive research, collaboration, and adherence to regulatory requirements set by authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA). This article serves as a comprehensive regulatory explainer manual, addressing how to effectively utilize literature, workshare, and prior findings in streamlining the…

How to plan safety pharmacology for small molecules vs biologics INDs How to Plan Safety Pharmacology for Small Molecules vs Biologics INDs Introduction to Safety Pharmacology and IND Requirements In the domain of drug development, the transition from preclinical to clinical stages is a critical juncture, particularly when submitting an Investigational New Drug (IND) application. Safety pharmacology is a vital component of this process, guiding the assessment of potential adverse effects of a new therapeutic before human trials commence. Both small molecules and biologics require a thorough understanding of safety pharmacology, yet the specific regulatory pathways and study expectations differ…

Nonclinical strategies for rare disease and orphan drug IND submissions Nonclinical Strategies for Rare Disease and Orphan Drug IND Submissions The development of orphan drugs for rare diseases poses unique challenges, particularly in meeting the IND nonclinical requirements. Regulatory agencies such as the FDA, EMA, and MHRA provide guidelines that are pivotal to navigate the complexities encountered during the Investigational New Drug (IND) submission process. This article aims to outline the critical nonclinical strategies necessary for successful IND submissions for orphan drugs, focusing on the requisite nonclinical toxicology studies, pharmacology data, and pre-IND meeting strategies. Understanding IND Nonclinical Requirements The…

Integrating nonclinical, CMC and clinical plans in an IND briefing package Integrating Nonclinical, CMC, and Clinical Plans in an IND Briefing Package The submission of an Investigational New Drug (IND) application marks a crucial milestone in the drug development process. It serves as a formal request to the U.S. Food and Drug Administration (FDA) for authorization to administer an investigational drug to humans. This process is not only pivotal for pharmaceutical companies aiming to enter clinical trials but also demands a comprehensive understanding of nonclinical, Clinical Manufacturing and Controls (CMC), and clinical strategy. This article aims to provide a detailed…